Insys to pay $225 million, unit to plead guilty to settle U.S. opioid charges

Insys Therapeutics Inc agreed to pay $225 million and an operating unit agreed to plead guilty to five mail fraud counts to settle criminal and civil probes into its marketing of opioids, the U.S. Department of Justice said on Wednesday.